Interestingly, mouse models for RTT using MeCP2 KO mice crossed with mice with CX3CR1 mutations recovered the MeCP2 deficient phenotype, suggesting that blocking the fracktalkine receptor is a possible therapeutic approach for RTT (79). Here, MECP2 is linked to Rett syndrome.